Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New cathepsin K inhibitors developed at Merck Frosst

May 28, 2004

Nissan Chemical scientists design new TPO receptor agonists

May 28, 2004

Novel retinoid RXR partial agonists claimed as antidiabetic agents by Allergan

May 28, 2004

Insulin formulation allows absorption through the gastrointestinal tract

May 28, 2004

sNDA filed for once-monthly oral formulation of Boniva

May 28, 2004

Aventis claims glucose lowering agents for type 2 diabetes and other disorders

May 27, 2004

Arena develops antilipolytic agents targeting the nicotinic acid RUP25 receptor

May 27, 2004

Liraglutide shows promise in type 2 diabetes

May 27, 2004

DX-88 development placed on hold pending preclinical review

May 27, 2004

Ono claims new prostaglandin derivatives for use in bone disorders

May 26, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...